Peptides and GLP-1 receptor agonists are rapidly reshaping modern medicine, from weight loss clinics to sleep apnoea treatment rooms, but the clinical frameworks meant to govern their use are struggling to keep up.
A new narrative review published in Cureus examines one of the most unexpected downstream effects of this pharmaceutical shift: whether patients with obstructive sleep apnoea (OSA) can safely reduce or discontinue continuous positive airway pressure (CPAP) therapy after substantial weight loss induced by GLP-1 and dual incretin agonists.
The answer, according to the evidence, is not straightforward.
A treatment that improves one disease may destabilise another
GLP-1 receptor agonists and newer dual agonists such as tirzepatide have demonstrated significant weight loss effects, in some cases approaching levels previously seen only after bariatric surgery. Across multiple trials, these drugs have also been shown to reduce the apnoea-hypopnoea index (AHI), a key measure of sleep apnoea severity.
In the largest trials to date, patients experienced reductions in AHI of more than 20 events per hour on average, alongside weight loss nearing 20 percent of body mass in some groups. Around half of participants even reached a threshold where CPAP might no longer be required.
But that is where the certainty ends.
The remission problem no one has solved yet
The review highlights a critical gap in current clinical thinking: improvement in sleep apnoea is not the same as remission.
Even after significant weight loss, many patients remain in moderate disease categories where CPAP is still recommended. In fact, more than half of patients in major trials did not reach a level considered low enough to justify stopping therapy.
This raises a difficult question for clinicians already seeing patients asking to discontinue CPAP after starting GLP-1 therapy: what defines “safe enough” to stop?
Right now, no formal guideline exists.
Why stopping CPAP is not as simple as losing weight
The biological reality of sleep apnoea is more complex than body weight alone. While fat reduction around the airway plays a major role, researchers also point to non-weight-related mechanisms such as ventilatory control instability, low arousal thresholds, and impaired airway muscle responsiveness.
These factors may persist even after major weight loss, meaning the disease can remain active despite a transformed body composition.
The review also notes a key uncertainty: it is still unclear whether GLP-1 drugs improve sleep apnoea only through weight loss, or whether they also have direct effects on breathing control and sleep physiology.
If the latter is true, stopping the drug could theoretically worsen sleep apnoea even if weight remains stable.
What happens when therapy is withdrawn
Evidence from CPAP withdrawal studies adds another layer of caution.
When CPAP is stopped, obstructive events can return within days. Blood pressure increases, oxygen levels worsen, and symptoms reappear quickly in many patients. This suggests that sleep apnoea is highly responsive to treatment changes and may not remain stable after intervention removal.
In other words, improvement does not necessarily equal stability.
A booming drug class, but unclear exit rules
GLP-1 therapies are expanding rapidly into obesity, diabetes, cardiovascular risk reduction, and now sleep apnoea management. At the same time, demand is rising fast, with search interest for peptides reportedly increasing several-fold in the past year.
But while entry into treatment is becoming easier, exit strategies remain undefined.
The review argues that this is now a real clinical governance problem: patients are already stopping CPAP in practice after weight loss, even though evidence-based withdrawal protocols do not exist.
The proposed solution: structured de-escalation, not sudden stopping
Instead of abrupt discontinuation, the authors propose a structured reassessment framework. This includes:
- Confirming weight stability before any decision
- Repeating sleep studies off therapy
- Using strict severity thresholds before stopping CPAP
- Ongoing monitoring after withdrawal
- Immediate restart criteria if symptoms or weight return
The key idea is that CPAP withdrawal should be treated like a reversible experiment, not a permanent decision.
The bigger issue: medicine is moving faster than guidelines
The central message of the review is not that CPAP should be stopped or continued universally, but that current clinical systems are not designed for drug-induced structural weight loss of this scale.
With GLP-1 therapies expanding rapidly, clinicians are now making withdrawal decisions without randomized evidence, standardized thresholds, or long-term outcome data.
And that gap is widening.